207_Combined course Presentations

CROSS Trial Population: T1N1 or T2-T3-N0-1 and Tumour size between 5 and 8 cm Oesophageal or gastro-oesophageal junction tumours

Adenocarcinoma: 75% +++

Surgery n=188

RT/CT then Surgery n=178

Carbo AUC2 and Taxol 50 mg/m2 D1, 8, 15, 22, 29 RT: 41.4 Gy / 1.8 Gy by fraction Better tolerated than 5FU-Cisplatin (?)

N Engl J Med 2012;366:2074-84 Shapiro, Lancet Oncol 2015; 16: 1090–98